The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 08, 2023
Filed:
Jun. 19, 2018
Applicant:
Immunocore Limited, Abingdon, GB;
Inventors:
Philip William Addis, Abingdon, GB;
Nicole Joy Bedke, Abingdon, GB;
Lucie Bouard, Abingdon, GB;
Stephen Harper, Abingdon, GB;
Nathaniel Liddy, Abingdon, GB;
Tara Mahon, Abingdon, GB;
Ronan Pádraic O'Dwyer, Abingdon, GB;
Assignee:
Immunocore Limited, Abingdon, GB;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/725 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61K 35/17 (2015.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 35/17 (2013.01); A61K 45/06 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); A61K 38/00 (2013.01);
Abstract
The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.